Panobinostat (LBH589)

For research use only.

Catalog No.S1030 Synonyms: NVP-LBH589

279 publications

Panobinostat (LBH589) Chemical Structure

CAS No. 404950-80-7

Panobinostat (LBH589, NVP-LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 117 In stock
USD 90 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Panobinostat (LBH589) has been cited by 279 publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Panobinostat (LBH589, NVP-LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.
Targets
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. [1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 MkfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnqdW0xNTFyIN88US=> MlTuNE01KGR? MVPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MmTJNlY4ODJ5OES=
HepG2 MnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[2SFAuOTBizszN MWqwMVQh\A>? M3rLUIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Ml7INlY4ODJ5OES=
HT29 M{L6cmZ2dmO2aX;uJGF{e2G7 M4PW[lUxyqCwTR?= NH\wXnczPC15MjDo M3K0VIlv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmKDNiYX\0[ZIhPDkEoHlCpC=> M124VVI3PzB{N{i0
HepG2 NHPoSpFHfW6ldHnvckBCe3OjeR?= NHXIWJQ2OMLibl2= M1WwVFI1NTd{IHi= M{[zdYlv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmKDNiYX\0[ZIhOjUEoHlCpC=> M4XzR|I3PzB{N{i0
HCC827 NEHYRXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXW1M|cvPS9zMDDuUS=> MkS3O|LDqGh? MmD1SG1UVw>? MlTJ[Y5p[W6lZYOgeIhmKGGwdHnwdo9tcW[ncnH0bZZmKGWoZnXjeEBw\iCncnzveIlvcWJ? M4fHeFI3Pjd3NEi0
A549  NGTsO5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPtNVAwOTVxMkCgcm0> M3HBXlczyqCq M4nHR2ROW09? NEHq[o5mdmijbnPld{B1cGViYX70bZBzd2yrZnXyZZRqfmViZX\m[YN1KG:oIHXycI91cW6rYh?= MYGyOlY4PTR6NB?=
NCI-H460  NGT4UWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fhelExNzJyL{OwJI5O NFjITlU4OsLiaB?= MnTDSG1UVw>? NVf5XJM1\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK= M1PSflI3Pjd3NEi0
J89GFP NYKweHlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4j3N2ROW00EoB?= NVTXO3pwTUN3ME20PU45PSEEsTCxNk43PSCwTR?= M2fMT|I3PTZ|NU[4
THP89GFP MnraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTOSG1UV8Li M4n2XmVEPTB;MUmuN|QhyrFiNj60N{BvVQ>? NITHV4UzPjV4M{W2PC=>
SK-NEP-1 NVOyUZBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX2wMlAy6oDVMUCuNEDPxE1? MmiyNlQhcA>? NFPHZ2hFVVORwrC= MUHJR|UxRTd4LkO0JI5O NYf2eItEOjZzN{[yNVk>
G401 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TGS|AvODIkgKOxNE4xKM7:TR?= Mnr6NlQhcA>? MXnEUXNQyqB? M1zISGlEPTB;MUSzMlAzKG6P NWTuO4pUOjZzN{[yNVk>
SK-NEP-1 M3\USGNmdGxiVnnhZoltcXS7IFHzd4F6 MkPyOVAhdk1? M3m0VFHjiJN2IHS= M2n2dmROW00EoB?= NFjsRZZz\WS3Y3XzJINmdGxic4Xyeol3[WxiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ? NVrkVYZuOjZzN{[yNVk>
G401 NGP1fXdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3vqVFUxKG6P NFi3OY0y6oDVNDDk Mmj4SG1UV8Li MUDy[YR2[2W|IHPlcIwhe3W{dnn2ZYwhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> MlPDNlYyPzZ{MUm=
SK-NEP-1 M3izPGFxd3C2b4Ppd{BCe3OjeR?= M{jnVVUxNzFyMDDuUS=> NVjzPW5vOjRiaB?= MkfxSG1UV8Li MUPpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MUeyOlE4PjJzOR?=
G401 M4XobGFxd3C2b4Ppd{BCe3OjeR?= NETQTmk2OC9zMECgcm0> NX3wbmpNOjRiaB?= NVm0PZg6TE2VT9Mg M3myNYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXSyOlE4PjJzOR?=
SK-NEP-1 M374e2Z2dmO2aX;uJGF{e2G7 MnHsOVAwOTByIH7N NIDsO|YzPCCq NHrOOIZFVVORwrC= NI\BNIl{cG:5czD0bIUhcW6mdXP0bY9vKG:oIFTORUBnemGpbXXueIF1cW:w MX2yOlE4PjJzOR?=
G401 MV3GeY5kfGmxbjDBd5NigQ>? M3ricFUxNzFyMDDuUS=> MlT0NlQhcA>? M2LLWmROW00EoB?= M1W4RpNpd3e|IITo[UBqdmS3Y4Tpc44hd2ZiRF7BJIZz[WevZX70ZZRqd25? NV7Qc4dTOjZzN{[yNVk>
SK-NEP-1 NYjOdZFqTnWwY4Tpc44hSXO|YYm= NW\NUodIPTBxMUCwJI5O Mlr5NlQhcA>? MmS3SG1UV8Li NGDBT4dqdmS3Y3XzJINmdGxiY4njcIUh\Gm|b4Lk[ZLDqA>? NF;mPGczPjF5NkKxPS=>
G401 MXXGeY5kfGmxbjDBd5NigQ>? MYW1NE8yODBibl2= MUKyOEBp MlT3SG1UV8Li MnrlbY5lfWOnczDj[YxtKGO7Y3zlJIRqe2:{ZHXyxsA> NGHvc5YzPjF5NkKxPS=>
RPMI 8226 MX;D[YxtKFO3co\peoFtKEG|c3H5 NEH4VYMzNzRxNjDuUS=> NXXFelJIPDkkgJno NEDNXW1qdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq MX[yOlAxODJ7Mh?=
OPM2 M3SzcGNmdGxiU4Xyeol3[WxiQYPzZZk> M4\XSFIwPC94IH7N MnTxOFjjiImq NUHZbmt2cW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= NIOzR3ozPjByMEK5Ni=>
U266 NXLFR|FVS2WubDDTeZJ3cX[jbDDBd5NigQ>? NWHGOGk1Oi92L{[gcm0> MXW0PQKBkWh? MVnpcoR2[2W|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp M4PYNVI3ODByMkmy
H929 NFv0dVJE\WyuIGP1dpZqfmGuIFHzd4F6 NH7tXpEzNzRxNjDuUS=> NYrofVFvPDkkgJno NUf1SYljcW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= NXHQN2t1OjZyMECyPVI>
RPMI 8226  M4PLO2Fxd3C2b4Ppd{BCe3OjeR?= M3[3N|TjiImwTR?= NHfHUm0zPC92ODDo NHPiW4NqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NV\VcGE{OjZyMECyPVI>
HCC827 M2faUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkC1NVAhdk1? NGDhbJM1QCCq M1;LRmROW09? M{nEd4VvcGGwY3XzJINqe3CuYYTpckB{\W6|aYTpeol1gcLi M4HEOlI2QTR2NkG3
NCI-H23 Moi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoftNVAhdk1? NF7sXm41QCCq MUPEUXNQ MUPlcohidmOnczDjbZNxdGG2aX6gd4Vve2m2aY\peJnDqA>? Ml3iNlU6PDR4MUe=
AML3 NUXQO3IzTnWwY4Tpc44hSXO|YYm= Mlq4NE0yKM7:TR?= NFzwfFAzPMLiaB?= Mk\pbY5lfWOnczDEUmEh\nKjZ33lcpRifGmxbtMgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NUTRSZJ4OjV4MUK5OFE>
ML-1 NV;OWJNoTnWwY4Tpc44hSXO|YYm= NXrkRm5bOC1zIN88US=> M{TFRlI1yqCq NY[4O2NjcW6mdXPld{BFVkFiZoLh[41mdnSjdHnvcuKhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NFjKfo8zPTZzMkm0NS=>
RPMI-8226vr10  MmjrSpVv[3Srb36gRZN{[Xl? MnLpNE0yKM7:TR?= M3q4XVI1yqCq NHrkUGFqdmS3Y3XzJGRPSSCocnHncYVvfGG2aX;uxsBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NFu1XJIzPTZzMkm0NS=>
ML-1 MlPwSpVv[3Srb36gRZN{[Xl? NH;WWnIyKM7:TR?= M1fidlI1yqCq MkDubY5kemWjc3XzJINie3Cjc3WtN{Bi[3Srdnn0fUA1NW[xbHS= MleyNlU3OTJ7NEG=
RPMI-8226vr10  M1;CUmZ2dmO2aX;uJGF{e2G7 NYDCfJFxOSEQvF2= NF;pRY8zPMLiaB?= MlzobY5kemWjc3XzJINie3Cjc3WtN{Bi[3Srdnn0fUAzNjVvZn;s[C=> NYDHNldtOjV4MUK5OFE>
SK-N-BE (2) NWjzcJB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPhNlTjiImq MnL3TWM2OD1zMESuNQKBkcLz4pEJO{45KG6P MmP3NlU{ODh7MU[=
SK-N-BE (2), PAN  MK MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIWxNJUzPOLCiXi= MYDJR|UxRTFyND6w5qCKyrIkgJm3Mlghdk1? MUCyOVMxQDlzNh?=
SK-N-BE (2), MK  PAN Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfZNlTjiImq NY\DSnZwUUN3ME2zPFIvOOLCidMx5qCKPDNwMjDuUS=> NYLCTWpnOjV|MEi5NVY>
SK-N-AS MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDWSJdpOjUkgJno NXnPOWtjUUN3ME2zO{4y6oDLwsJihKkzNjRibl2= NWOx[ZF3OjV|MEi5NVY>
SK-N-DZ NVrrO5hwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;tdmdnOjUkgJno MWXJR|UxRTF5LkJihKnDueLCiUCuOEBvVQ>? MYSyOVMxQDlzNh?=
Caki-1 Mo\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIG0dFcyOC9{NT:1NEBvVQ>? MUC0PEBp MlvBbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{ MmnlNlUzPzlzOUG=
ACHN M{C1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY[xNE8zPS93MDDuUS=> Mn22OFghcA>? MX\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ? MX2yOVI4QTF7MR?=
769-P MnPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HKPVExNzJ3L{WwJI5O MXm0PEBp MnSxbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{ MlnWNlUzPzlzOUG=
786-O  NYfHOI9qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXocVIyOC9{NT:1NEBvVQ>? M1\tZVQ5KGh? MYfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ? NViySItkOjV{N{mxPVE>
Caki-1 NHXUcohCeG:ydH;zbZMhSXO|YYm= NV\sWXVzPTBibl2= Ml25OFghcA>? NXm0V5hZcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK= NGnsNYszPTJ5OUG5NS=>
ACHN NI\0XGlCeG:ydH;zbZMhSXO|YYm= MWG1NEBvVQ>? NEDxUFc1QCCq NGH6c|FqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= M1G2OFI2Ojd7MUmx
769-P M{TmcWFxd3C2b4Ppd{BCe3OjeR?= Mn:zOVAhdk1? NGL6ZXI1QCCq NGDq[GRqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= Mn3INlUzPzlzOUG=
786-O  MoDRRZBweHSxc3nzJGF{e2G7 Mn[zOVAhdk1? NYX2VGZZPDhiaB?= NU\kU4RkcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK= MYKyOVI4QTF7MR?=
Caki-1 NXP4R4tPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TDVlI2NzVyIH7N MnrxOFghcA>? NHjVbnBFVVOR MYLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk MYCyOVE4PjN3NB?=
ACHN M3TFfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2r1dVI2NzVyIH7N Mn7uOFghcA>? M3rqUWROW09? NILtU4hqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni MmjMNlUyPzZ|NUS=
769-P NEnP[oVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PleVI2NzVyIH7N NYTsU4FSPDhiaB?= MoHLSG1UVw>? M3XjVolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIHLvdpRmgm:vaXK= M17x[VI2OTd4M{W0
Caki-1 MV3Dc4xwdnliRn;ycYF1cW:wIFHzd4F6 M4DpclUxKG6P MVm3MVE1KGR? NIDQNGRFVVOR NXL6VlNpe3WycILld5Nm\CClb3zvcpkh\m:{bXH0bY9vKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCC5aYToJIJwenSnen;tbYIhyqB? MmftNlUyPzZ|NUS=
ACHN MUfDc4xwdnliRn;ycYF1cW:wIFHzd4F6 NXfaO21pPTBibl2= MX63MVE1KGR? MkXhSG1UVw>? NF\4NW5{fXCycnXzd4VlKGOxbH;ufUBnd3KvYYTpc44he2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKHerdHigZo9zfGW8b33pZkDDqA>? NYjIcYZkOjVzN{[zOVQ>
769-P NFTLdHVEd2yxbomgSo9zdWG2aX;uJGF{e2G7 MWq1NEBvVQ>? M3\SVFcuOTRiZB?= M{DEZWROW09? MUjzeZBxemW|c3XkJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJJdqfGhiYn;yeIV7d22rYjFCpC=> MnXrNlUyPzZ|NUS=
Caki-1 NIHtWFhCeG:ydH;zbZMhSXO|YYm= NUfzT5JVPTBibl2= M3KzWFQ5KGh? M1zzZ2ROW09? NH7kRYtqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NWe2OYJtOjVzN{[zOVQ>
ACHN MWPBdI9xfG:|aYOgRZN{[Xl? MWC1NEBvVQ>? NIPwTYE1QCCq MYLEUXNQ MlG5bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MkfKNlUyPzZ|NUS=
769-P M{SzR2Fxd3C2b4Ppd{BCe3OjeR?= NF;jdHY2OCCwTR?= M4TFblQ5KGh? NEXidFNFVVOR MkmybY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NH2wPZQzPTF5NkO1OC=>
MDA-MB-231 NH;TcWlOd3KyaH;sc4dq[2GuIFPyfZN1[WxiVnnvcIV1KCiFVjmgRZN{[Xl? M{\EOlExyqCwTR?= MljaN:Kh\A>? MW\EUXNQ MU\hcJRmenNiY3XscEBud3KyaH;sc4d6yqB? M{HM[|I1QDFyNEm3
BT-549 MnPYUY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6 NXn1fm1IOTEEoH7N NXLVZ4hkO8LiZB?= M1jBWWROW09? NFey[4hidHSncoOgZ4VtdCCvb4LwbI9td2e7wrC= M4\vOlI1QDFyNEm3
MCF-7  NUXqWZl3VW:{cHjvcI9ocWOjbDDDdpl{fGGuIG\pc4xmfCBqQ2[pJGF{e2G7 MXWxNOKhdk1? Mn7pN:Kh\A>? MXPEUXNQ MVrhcJRmenNiY3XscEBud3KyaH;sc4d6yqB? M3fnOVI1QDFyNEm3
MCF-7 NULSV|ZvTnWwY4Tpc44hSXO|YYm= M{LQdFUuPTBibl2= MYSyOEBp NIDJRpJFVVOR M2jxOJJm\HWlZXSgeIhmKGyndnXsJI9nKGW6cILld5Nqd25ib3[gSXLPuSxiUGKgZY5lKE[xeFGxxsA> MlO2NlQ{PjZ2MEe=
CTS NGnMR2FCeG:ydH;zbZMhSXO|YYm= M1LFd|DjiJN2MDDuUeKh NGKyeIM1QCCq MXTpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Mnq4NlQzPDR2Mkm=
OCI-AML3  M1;CS2Fxd3C2b4Ppd{BCe3OjeR?= M1rsbFDjiJN2MDDuUeKh MXm0PEBp NFeyUmJqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M3e2fVI1OjR2NEK5
U937 MWDBdI9xfG:|aYOgRZN{[Xl? MV2w5qCUPDBibl5CpC=> MWe0PEBp M1;ZO4lv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M{XIVlI1OjR2NEK5
PC3 MXLBdI9xfG:|aYOgRZN{[Xl? MYqwMVExOCCwTR?= M3zwRVI1NzR6IHi= MkW5bY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NE\wV|YzPDF4M{KzNC=>
PC3-AR NFvsWGtCeG:ydH;zbZMhSXO|YYm= M{LMNFAuOTByIH7N Mor5NlQwPDhiaB?= MUPpcoR2[2W|IHHwc5B1d3OrczDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M3HOeVI1OTZ|MkOw
PC3 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYm3RmdiOC1zMECgcm0> M3q5[|I1NzR6IHi= M13oZ4lv\HWlZYOgZYNkfW23bHH0bY9vKG:oIIP1ZmcyKHCxcIXsZZRqd25? M{\lO|I1OTZ|MkOw
PC3-AR M4\tV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPNTFIxNTFyMDDuUS=> NEDFZpIzPC92ODDo NETCVndqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIlvKHSqZTDHNm0heGijc3W= M4rkcFI1OTZ|MkOw
PC3 Ml\ISpVv[3Srb36gRZN{[Xl? MoLTNE0yODBibl2= NFzadlAzPCCq MX;zeZBxemW|c3XzJIV5eHKnc4Ppc44hd2ZiYXP0bZZifGWmIFHUUUwhSWu2IHHu[EBGemtzL{KgdJJwfGWrbh?= MlLlNlQyPjN{M{C=
PC3-AR MofWSpVv[3Srb36gRZN{[Xl? Ml7QNE0yODBibl2= NULMcGhEOjRiaB?= NIjWTox{fXCycnXzd4V{KGW6cILld5Nqd25ib3[gZYN1cX[jdHXkJGFVVSxiQXv0JIFv\CCHcnuxM|IheHKxdHXpci=> NFHUTm8zPDF4M{KzNC=>
OS-RC-2 Mk\xR4VtdCCYaXHibYxqfHliQYPzZZk> MXKwMVExODBibl2= MXeyOE81QC95MjDo NE\TNIxFVVOR MYnk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M1n6dVI1OTR2N{O3
OS-RC-2 NHPaPGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHBb3o2OCCwTR?= MUK0PEBp MYLEUXNQ NGjtOWNqdmS3Y3XzJGczN01iYYLy[ZN1 NFXU[5EzPDF2NEezOy=>
OS-RC-2 MWPBdI9xfG:|aYOgRZN{[Xl? MljBOVAhdk1? M3vF[VQ5KGh? NYnKPZNlTE2VTx?= M2PLO4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M{Xj[lI1OTR2N{O3
SK-N-AS M{DneGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTzO3JJOOLCk{iwJI5O MYq0PEBp NV;YWVNnUUN3ME2yO{41KG6P MYWyOFA6QDd7OR?=
SK-N-DZ MnrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTVcIJ4OOLCk{iwJI5O NVPGfI1bPDhiaB?= NYrYbJdpUUN3ME2yNU46KG6P NYS4eVRZOjRyOUi3PVk>
SK-N-SH M3H6VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLKNQKBmzhyIH7N NUXIZZM5PDhiaB?= MkfNTWM2OD15Mj6zJI5O NWC2RZh7OjRyOUi3PVk>
SK-N-BE NUfLOZY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnqNQKBmzhyIH7N MXm0PEBp MYrJR|UxRTd3LkSgcm0> M4rnWlI1ODl6N{m5
SK-N-AS Mn7nRZBweHSxc3nzJGF{e2G7 NHjjUVAx6oDVOECgcm0> NWKxd3psPDhiaB?= MorNdI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u MV6yOFA6QDd7OR?=
SK-N-DZ NFrp[VJCeG:ydH;zbZMhSXO|YYm= NF7rNXkx6oDVOECgcm0> M37pflQ5KGh? NVTHfYxOeG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v NHfNUHgzPDB7OEe5PS=>
SK-N-SH NYP5TmVUSXCxcITvd4l{KEG|c3H5 MUWw5qCUPDBibl2= Mln0OFghcA>? MUHwc5RmdnSueTDpcoR2[2WmIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36= NH3jOJYzPDB7OEe5PS=>
SK-N-BE NVfWR4lpSXCxcITvd4l{KEG|c3H5 Mny1NQKBmzRyIH7N NYD3TVB6PDhiaB?= MX3wc5RmdnSueTDpcoR2[2WmIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36= MX[yOFA6QDd7OR?=
SK-N-AS NUDlVmpQTnWwY4Tpc44hSXO|YYm= MWSw5qCUQDBibl2= MlywOFghcA>? M4C1SYlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA> NVrwPVd{OjRyOUi3PVk>
SK-N-DZ MXnGeY5kfGmxbjDBd5NigQ>? NY\Gdlc{OOLCk{iwJI5O M{TrO|Q5KGh? MV;pcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG|ZTCzJIFv\CCSQWLQ NW\hVZdEOjRyOUi3PVk>
SK-N-SH NFzyUYZHfW6ldHnvckBCe3OjeR?= MkLBNQKBmzRyIH7N MYG0PEBp Mmr3bY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=> MWCyOFA6QDd7OR?=
SK-N-BE MXXGeY5kfGmxbjDBd5NigQ>? MlrkNQKBmzRyIH7N NVfTNIRqPDhiaB?= MkLKbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=> NIr6T4gzPDB7OEe5PS=>
HCC-LM3 NXmxbIltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUmxMVExODBibl2= MoDBNlQwPDhxN{KgbC=> NEDCPItFVVOR M2G0V4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NF;3cXUzPDB7M{m1Oi=>
HepG2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX[xMVExODBibl2= NGnJRWQzPC92OD:3NkBp NYnzd49PTE2VTx?= MVvpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M{[4[VI1ODl|OUW2
SMMC-7721 NETzV2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3aXpgyNTFyMECgcm0> MXSyOE81QC95MjDo MkK2SG1UVw>? M4fZOYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NVmyO|JVOjRyOUO5OVY>
HCC-LM3 NXfLN5JwSXCxcITvd4l{KEG|c3H5 M{n4R|UxKG6P MVK0PEBp M{TOPGROW09? NXzVeYpTcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGmwIHGgZ4F{eGG|ZT3k[ZBmdmSnboSgcYFvdmW{IHL5JINt\WG4YXflJI9nKGOjc4Dhd4V{KDNuIEigZY5lKDl? M4TybFI1ODl|OUW2
HepG2 NYG0fmc3SXCxcITvd4l{KEG|c3H5 MlPROVAhdk1? M4XpfFQ5KGh? M1zUVGROW09? MmfrbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5JIlvKGFiY3HzdIF{\S2mZYDlcoRmdnRibXHucoVzKGK7IHPs[YF3[WenIH;mJINie3Cjc3XzJFMtKDhiYX7kJFk> MWSyOFA6Ozl3Nh?=
SMMC-7721 NHi4NI1CeG:ydH;zbZMhSXO|YYm= MmHiOVAhdk1? MmTxOFghcA>? MlfhSG1UVw>? NHPwO|RqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJkhcW5iYTDjZZNx[XOnLXTldIVv\GWwdDDtZY5v\XJiYomgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[ZMhOyxiODDhcoQhQQ>? NY\XN2NHOjRyOUO5OVY>
HCC-LM3 Ml;nSpVv[3Srb36gRZN{[Xl? MnvjOVAwOTByIH7N MnLTNlQhcA>? MUXEUXNQ NHTWNFFl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR|IHHu[EBxNUGtdNMg M1LOO|I1ODl|OUW2
HepG2 MmTqSpVv[3Srb36gRZN{[Xl? MX61NE8yODBibl2= NGnEcJQzPCCq NHK1e|RFVVOR MX7k[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCyLWPURXQ{KGGwZDDwMWFsfMLi MU[yOFA6Ozl3Nh?=
SMMC-7721 Mk\0SpVv[3Srb36gRZN{[Xl? MXW1NE8yODBibl2= NWm4S|l7OjRiaB?= NGG5UphFVVOR MXLk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCyLWPURXQ{KGGwZDDwMWFsfMLi NYf4[G5OOjRyOUO5OVY>
HCC-LM3 M3HWOmZ2dmO2aX;uJGF{e2G7 M4TadVUxNzFyMDDuUS=> M4[xN|I1KGh? NH:y[lFFVVOR MnT6[I94dnKnZ4XsZZRmeyCEY3ytfGwh\XiycnXzd4lwdg>? M4rOOlI1ODl|OUW2
HepG2 NFLBNHJHfW6ldHnvckBCe3OjeR?= M3H0VVUxNzFyMDDuUS=> NWDVSHhJOjRiaB?= M{LjW2ROW09? NYPme3o5\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?= MUeyOFA6Ozl3Nh?=
SMMC-7721 M1nuZmZ2dmO2aX;uJGF{e2G7 M1rOZVUxNzFyMDDuUS=> MoSzNlQhcA>? M1LINGROW09? NVSySm1[\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?= M{fGU|I1ODl|OUW2
FaDu M4DvdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[1c2QyODEkgJXuUS=> MUi4M|ExNzF{IHi= Ml2z[Il{eGyjeXXkJIEhe2mpbnnmbYNidnRiYX7kJJBzd2yxbnfl[EBIOi:PIHHydoV{fCCjdDC4JIFv\CBzMvMAiYgheG:|dDDy[Yxm[XOn M1T2WVI1ODJ4NEiy
FaDu NHHuWW5HfW6ldHnvckBCe3OjeR?= MnLrNVAx6oDHbl2= NFi2dGIzNzRxOD:xNkBp NX[2VVZpcW6mdXPl[EBxOjGZYX[xM2NqeDIEoHX4dJJme3Orb36= NXLjeGd{OjRyMk[0PFI>
PC-3  M3KzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofxNE0yOCEQvF2= MYCyOE81QC95MjDo NFvKRXpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NELz[4wzOzl7MUKxOi=>
LNCaP NXThb5I1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TtRlAuPSEQvF2= M3zhUlI1NzR6L{eyJIg> NXLq[IdDcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MkjCNlM6QTF{MU[=
RWPE-1  NFnSXpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{WyNFAuOjBizszN MojNNlQwPDhxN{KgbC=> NV;6XlhrcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M{fYN|I{QTlzMkG2
Capan-1 M3yy[WZ2dmO2aX;uJGF{e2G7 NFnEb2EzPS93MD:xNFAhdk1? MlrUPE8zPC92ODDo MVrEUXNQ NFzrOo1ld3ewcnXneYxifGWmIGLvckBuWk6DIHHu[EBxem:2ZXnuJIV5eHKnc4Ppc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7n MVqyN|kzOjh6Nh?=
L3.6pl M13lVmZ2dmO2aX;uJGF{e2G7 MknXNlUwPTBxMUCwJI5O M2PYVlgwOjRxNEigbC=> M4X5SWROW09? NVHXcIlp\G:5boLl[5Vt[XSnZDDSc44hdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[y=> MmDNNlM6OjJ6OE[=
CFPAC-1  NEfjT|VHfW6ldHnvckBCe3OjeR?= NHm5[3czPS93MD:xNFAhdk1? NF7PboY5NzJ2L{S4JIg> NGi0VIJFVVOR MYDkc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p MYSyN|kzOjh6Nh?=
Capan-1 M{DPW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXKyOU82OC9zMECgcm0> MkLmOFghcA>? NFq3U2pFVVOR M2\ufZJm\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MVOyN|kzOjh6Nh?=
L3.6pl Mn7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDPc3QzPS93MD:xNFAhdk1? M2XIblQ5KGh? NUm4N5BHTE2VTx?= NEjIOpFz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NF\QToczOzl{Mki4Oi=>
CFPAC-1  MnH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUP5UYR5OjVxNUCvNVAxKG6P M{L4cVQ5KGh? NWDZb3pXTE2VTx?= NVjhVII5emWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M1;KelI{QTJ{OEi2
Capan-1 NY\RVnVoSXCxcITvd4l{KEG|c3H5 Mlr1NlUwPTBxMUCwJI5O NUDJbYN[PDhiaB?= MXvEUXNQ NGjr[VVqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MoPmNlM6OjJ6OE[=
L3.6pl MnHyRZBweHSxc3nzJGF{e2G7 MV:yOU82OC9zMECgcm0> M{fsO|Q5KGh? NFi0eVlFVVOR Mmn6bY5lfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MXmyN|kzOjh6Nh?=
CFPAC-1  NUfUV5NwSXCxcITvd4l{KEG|c3H5 M2X3bFI2NzVyL{GwNEBvVQ>? M4f6WVQ5KGh? MV\EUXNQ M2PDd4lv\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NUj0TopbOjN7MkK4PFY>
HN22 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzhdHMxNTJyIH7N MXuyOE81QCCq NI\1UI5FVVOR NEmxdlJqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz Mn;1NlM5Pzd{M{W=
HSC4  MnzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnifm04OC1{MDDuUS=> MY[yOE81QCCq MmH3SG1UVw>? NWLvW4tpcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? NVuxdplwOjN6N{eyN|U>
HN22 M1vu[mFxd3C2b4Ppd{BCe3OjeR?= MYSwMVIxKG6P MmLJOFghcA>? NIXMWmVFVVOR NITFb41qdmS3Y3XzJINmdGxiYYDvdJRwe2m| MYiyN|g4PzJ|NR?=
HSC4  NEHSPVZCeG:ydH;zbZMhSXO|YYm= NH3i[Y4xNTJyIH7N NYLzSYM{PDhiaB?= MoToSG1UVw>? MXvpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MU[yN|g4PzJ|NR?=
HN22 MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nqUFAuOjBibl2= MoDROFghcA>? NXfBVpRpTE2VTx?= M4r2cIlv\HWlZYOgS|EheGijc3WgZ4VtdCCleXPs[UBienKnc4VCpC=> MlPWNlM5Pzd{M{W=
HSC4  MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHizdGQxNTJyIH7N M{HqdFQ5KGh? M{X3RmROW09? NEj6bIFqdmS3Y3XzJGcyKHCqYYPlJINmdGxiY4njcIUh[XK{ZYP0xsA> Mor0NlM5Pzd{M{W=
HN22 MYXGeY5kfGmxbjDBd5NigQ>? NIjaRW4xNTJyIH7N MoTJOFghcA>? M3\oXGROW09? M1fQTpN2eHC{ZYPz[ZMhW3BzIHX4dJJme3Orb39CpC=> NUTjbGdWOjN6N{eyN|U>
HSC4  Ml:5SpVv[3Srb36gRZN{[Xl? M2\o[FAuOjBibl2= M3P3UlQ5KGh? MYHEUXNQ NVjqO|FQe3WycILld5NmeyCVcEGg[ZhxemW|c3nvcuKh NVnyVZZVOjN6N{eyN|U>
Cal62 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\2TWM2OD1|MzFCtUA1KG6P M2nlVVI{QDJ2ME[0
Hth7 MmnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjjdVVKSzVyPUG1JOKyKDJibl2= MX[yN|gzPDB4NB?=
Hth83 M{PJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PMUWlEPTB;M{SgxtEhPSCwTR?= NEPacokzOzh{NEC2OC=>
C643 M2jTeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIq0b3BKSzVyPUexJOKyKDFyIH7N M1X1V|I{QDJ2ME[0
SW1736 M{fOZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTN3INMxJFghdk1? NW\aS4VlOjN6MkSwOlQ>
T241 MoK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTZ3INMxJFchdk1? NGjk[2czOzh{NEC2OC=>
T351 Ml\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVS5NFdWUUN3ME21NEDDuSBzMDDuUS=> NGDBNZUzOzh{NEC2OC=>
BHP2-7 M{D6VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fsfWlEPTB;M{egxtEhPiCwTR?= M3G0d|I{QDJ2ME[0
T238 Mor5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTTZnJKSzVyPUGsOVAxKMLzIEKwNEBvVQ>? M331RVI{QDJ2ME[0
HCT8 M4rDbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXyeW5lPzJiaB?= NF7mbm5FVVOR NVy4[lZ6UUN3ME2xNk466oDLwsJihKkyNjlibl2= MV6yN|I6QTN6OB?=
H630 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDmO|IhcA>? M37kXWROW09? MmL3TWM2OD1zMj605qCKyrIkgJmzMlEhdk1? M{K0TFI{Ojl7M{i4
cH630 5-FU-res MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nQOFczKGh? NVjDZZpRTE2VTx?= M{XQOGlEPTB;MUWuOgKBkcLz4pEJNU4zKG6P MnPhNlMzQTl|OEi=
HCT116 NE\2[nlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;6VpRMPzJiaB?= MYPEUXNQ NXix[lE{UUN3ME2xNE446oDLwsJihKkzNjJibl2= M3TZdFI{Ojl7M{i4
HCT116 p53−/− NUDYOmp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7FZVg4OiCq M2\JfmROW09? MYXJR|UxRThwNvMAjeKy6oDLMT63JI5O M3W1OlI{Ojl7M{i4
dHCT116 p21−/− NEToWXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGm3SG04OiCq MUXEUXNQ Mlz4TWM2OD13LkpihKnDueLCiUGuN{BvVQ>? MVuyN|I6QTN6OB?=
HT29 NWq4[I5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\sTFczKGh? MWTEUXNQ MYLJR|UxRTF4LkRihKnDueLCiUKuN{BvVQ>? NV7oUIZ5OjN{OUmzPFg>
LoVo Ml\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{f0SFczKGh? MnPQSG1UVw>? MkTzTWM2OD13LkJihKnDueLCiUCuOkBvVQ>? NV3qZ3lxOjN{OUmzPFg>
RKO NFn5bnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTNO|IhcA>? Ml64SG1UVw>? M{HjcWlEPTB;Nz655qCKyrIkgJmyMlIhdk1? NEXWPFQzOzJ7OUO4PC=>
SW480 M3[zcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moq4O|IhcA>? MXzEUXNQ MX7JR|UxRTF5LkZihKnDueLCiUCuPEBvVQ>? M1PDO|I{Ojl7M{i4
eSW620 M1f3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3VZ|ZXPzJiaB?= MojFSG1UVw>? NE\GeJhKSzVyPUmuNgKBkcLz4pEJNk4yKG6P MoPFNlMzQTl|OEi=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
DNMT1 / EZH2; 

PubMed: 19279403     


Western blot of DNMT1 and EZH2 in K562 and LAMA84 following 24 hours treatment with the indicated doses of panobinostat (PS). The levels of β-actin served as the loading control.

caspase-8 / cleaved caspase-8 / Sp1; 

PubMed: 27738323     


The indicated MM cell lines were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of caspase-8, cleaved caspase 8 and Sp1 were analyzed by Western blotting. 

c-Myc / IRF4; 

PubMed: 27738323     


RPMI8226 cells were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of cMyc and IRF4 were analyzed by Western blotting.

Ac-H3 / cleaved caspase-3 / CCND1 / ID1 / ID2 / ID3 / ID4 / Synaptophysin / NeuroD1; 

PubMed: 28915627     


Immunoblotting of whole cell lysates prepared from MB cells treated with panobinostat. The representative western blot result shows panobinostat clearly regulated acetyl-Histone H3 (Ac-H3), cleaved caspase-3, CCND1, IDs, synaptophysin and NeuroD1.

RAD51 / BRCA1 / CHK1 / RPL13a; 

PubMed: 24244429     


CTS, OCI-AML3 or U937 AML cells were treated with variable concentrations of panobinostat for 48 h. Whole cell lysates were subjected to Western blotting to measure protein levels for BRCA1, CHK1, and RAD51 in the cells.

H3K9AC / H3K18AC / H3K56AC / H3 / H4K8AC / H4K16AC / H4 / p21 / p27 / cleaved PARP; 

PubMed: 31071955     


Immunoblot analyses of histone acetylation (H3K9AC, H3K18AC, H3K56AC, H4K8AC and H4K16AC), cell cycle arrest (p27 and p27) and apoptotic-related protein (C-Caspase 3 and C-PARP) expression following various panobinostat treatments for 6 h and 24 h on K562 cells. H3, H4 and GAPDH immunoblots served as internal controls.

19279403 27738323 28915627 24244429 31071955
Immunofluorescence
Synaptophysin / NACM; 

PubMed: 28915627     


Panobinostat treated cells are positive for (B) synaptophysin (red) and (C) NCAM (red). Scale bars, 50 μm.

α-tubulin / Acetyl-α-tubulin; 

PubMed: 29983882     


CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) using the appropriate excitation and emission filters as described in the material and methods section. Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-nuclei (blue) at 100× magnification are shown. Scale bar, 5 μm.

BiP; 

PubMed: 23544167     


Immunofluorescence analysis of BiP after 24 and 48 hours of treatment in HepG2 (upper panel) and Hep3B (lower panel) cells with 0.1 µM panobinostat and 10 nM thapsigargin, showing an increase and a different protein distribution in panobinostat-treated cells, comparable to 10 nM thapsigargin effect, used as a positive control. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

ATF4; 

PubMed: 23544167     


HepG2 (left panel) and Hep3B (right panel) cells were treated for 24 and 48 hours with 0.1 µM panobinostat and the immunofluorescence results show an increase of ATF4 and its nuclear localization in both cell lines. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

IRE1α / S724-IRE1α; 

PubMed: 23544167     


Analysis of IRE1α/XBP1 involvement. Immunofluorescence results of IRE1α and its phosphorylated form in HepG2 (A) and Hep3B (B) cell lines after 24 and 48 hours of treatment with 0.1 µM panobinostat. The results indicate that panobinostat induces an increase of both the total and the phosphorylated form of IRE1α and a spotted distribution of this protein (enlargement showed for phospho-IRE1α, B). Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

28915627 29983882 23544167
Growth inhibition assay
Cell viability; 

PubMed: 27738323     


The indicated MM cell lines were cultured in triplicate in the absence or presence of panobinostat at the indicated concentrations. After culturing for 48 hours, cell viability was measured by a WST-8 cell proliferation assay. Results were expressed as the mean +/− SD.

27738323
In vivo In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. [2]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
  • Concentrations: 50 nM
  • Incubation Time: 48 hours
  • Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 104 cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (107 cells) or A549 (5 × 106 cells), H69 (2.5 × 106 cells), BK-T (6.5 × 106), H526 (10 × 106), and RG1 (10 × 106) cells
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: Administered via i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 349.43
Formula

C21H23N3O2

CAS No. 404950-80-7
Storage powder
in solvent
Synonyms NVP-LBH589
Smiles CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)C=CC(=O)NO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04341311 Recruiting Drug: Marizomib|Drug: Panobinostat Diffuse Intrinsic Pontine Glioma|Pediatric Brainstem Glioma|Pediatric Brainstem Gliosarcoma Recurrent|Pediatric Cancer|Pediatric Brain Tumor|Diffuse Glioma Dana-Farber Cancer Institute|Celgene|Secura Bio August 10 2020 Phase 1
NCT03632317 Withdrawn Drug: Panobinostat|Drug: Everolimus Glioma|Diffuse Intrinsic Pontine Glioma University of Michigan Rogel Cancer Center October 2019 Phase 2
NCT03982134 Withdrawn Drug: PDR001|Drug: Panobinostat Melanoma|Non Small Cell Lung Cancer Muhammad Furqan|Novartis Pharmaceuticals|University of Iowa September 2019 Phase 1
NCT04326764 Recruiting Drug: Panobinostat Acute Myeloid Leukaemia (AML)|Myelodysplastic Syndromes (MDS) Goethe University|Jan J. Cornelissen (HOVON-SAKK)|Sebastian Giebel (PALG) July 24 2018 Phase 3
NCT03515915 Unknown status -- Patients With Recurrent or Refractory Multiple Myeloma University Hospital Montpellier|Poitiers University Hospital April 23 2018 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo mice study?

  • Answer:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Panobinostat (LBH589) | Panobinostat (LBH589) supplier | purchase Panobinostat (LBH589) | Panobinostat (LBH589) cost | Panobinostat (LBH589) manufacturer | order Panobinostat (LBH589) | Panobinostat (LBH589) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID